Navigation Links
Gen-Probe Board of Directors Elects Carl Hull Chief Executive Officer

- Hank Nordhoff, CEO Since 1994, to Serve as Non-Executive Chairman of the Board -

SAN DIEGO, March 23 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that its board of directors has elected Carl W. Hull the Company's new chief executive officer (CEO), effective May 18, 2009. He also is expected to join the Company's board of directors at that time.

Mr. Hull, currently Gen-Probe's president and chief operating officer, will become president and CEO following the retirement of Henry L. Nordhoff as the Company's CEO on May 17, 2009. Mr. Nordhoff, who has served as Gen-Probe's chief executive officer since 1994, will become non-executive chairman upon his re-election to the board by stockholders at the Company's 2009 annual meeting.

"I'm delighted to announce the board's unanimous election of Carl as Gen-Probe's next CEO," Nordhoff said. "He brings unparalleled experience in our field and a deep understanding of molecular diagnostics. His keen intellect and unflagging energy will prove invaluable as he takes the helm of the Company."

"In nearly 15 years as CEO of Gen-Probe, Hank has presided over tremendous business growth, product innovation and shareholder value creation," said Armin Kessler, Gen-Probe's lead independent director and former chief operating officer of Hoffman-La Roche. "The Company has grown from a subsidiary of Chugai, with $61 million in annual revenues, to a public company with a market capitalization exceeding $2 billion and revenues of $473 million last year. Gen-Probe's customers, employees and shareholders owe him a debt of gratitude, and the board is fortunate to be able to continue benefiting from his guidance and leadership."

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has more than 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more information, go to

Caution Regarding Forward-Looking Statements

Any statements in this press release relating to expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. For example, statements regarding future growth, the composition of the board of directors, and the plans and objectives of management are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied. Some of these risks include, but are not limited to, the risk that we cannot retain key executives. For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports. We assume no obligation and expressly disclaim any duty to update forward-looking statements to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.


    Michael Watts
    Vice president, investor relations and corporate communications

SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Tepnel Shareholders Approve Acquisition by Gen-Probe
2. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008
3. Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash
4. Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration
5. Eric Tardif Joins Gen-Probe as Senior Vice President, Corporate Strategy
6. Gen-Probe to Webcast Presentation at the 27th Annual J.P. Morgan Healthcare Conference
7. Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference
8. Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance
9. Gen-Probe Announces Webcasts of Three Upcoming Investor Events
10. Gen-Probe to Webcast Two Upcoming Investor Presentations
11. Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a ... sleep tracking systems. The new app features a more intuitive SleepScore™ that rates sleep ... well you slept. The SleepScore is created by a proprietary algorithm. Beddit analyzes the ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, ... from Bronx, N.Y. “I thought there had to be a convenient and comfortable way ... , The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. ...
(Date:11/25/2015)... Md (PRWEB) , ... November 25, 2015 , ... ... Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for ... of this disease. The Periwinkle Pioneers, nominated by the public, will receive special ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely ... resulting in a way for homeless people to have a more dignified and ... new initiative whereby they are repurposing plastic bags into sleeping mats for the ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... on providing comprehensive solutions involving adult stem cell therapies to patients with chronic ... the “Regenestem” name as a Registered Trademark (RTM). , Organizations are required to ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 Allergan plc ... company, and Rugen Therapeutics, a start-up  biotechnology company ... unmet CNS disorders and funded by the F-Prime ... have entered into an exclusive collaboration to support ... Autism Spectrum Disorders (ASD) and Obsessive Compulsive disorders ...
(Date:11/25/2015)... NEW YORK , November 25, 2015 ... global market of self-monitoring blood glucose devices was valued ... to grow with a CAGR of 5.7% during 2015 ... increasing geriatric population and increasing prevalence of diabetes. In ... about diabetes care is also contributing to the growth ...
(Date:11/25/2015)... November 25, 2015 Developmental, commercial, ... boosting the profitability of pharmaceutical products, says GBI ... and regulatory/legal strategies all play a key role ... GBI Research . --> Developmental, ... key role in boosting the profitability of pharmaceutical products, ...
Breaking Medicine Technology: